| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5550165 | SWEDISH ORPHAN | Pharmaceutical compositions for the treatment of hereditary tyosinemia type I |
Aug, 2013
(10 years ago) | |
| US9301932 | SWEDISH ORPHAN | Liquid pharmaceutical composition comprising nitisinone |
Feb, 2033
(8 years from now) | |
Orfadin is owned by Swedish Orphan.
Orfadin contains Nitisinone.
Orfadin has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Orfadin are:
- US5550165
Orfadin was authorised for market use on 18 January, 2002.
Orfadin is available in suspension;oral, capsule;oral dosage forms.
Orfadin can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.
The generics of Orfadin are possible to be released after 28 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-169) | Sep 01, 2020 |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 18 January, 2002
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: CAPSULE;ORAL; SUSPENSION;ORAL
ORFADIN family patents
